United Therapeutics Corp (STU:UTH)
€ 251 -5 (-1.95%) Market Cap: 11.20 Bil Enterprise Value: 9.25 Bil PE Ratio: 12.90 PB Ratio: 2.26 GF Score: 89/100

United Therapeutics Corp Announces the INCREASE Study Evaluating Tyvaso® in Pulmonary Hypertension Associated with Interstitial Lung Disease Transcript

Jan 19, 2021 / 09:30PM GMT
Release Date Price: €144 (+0.70%)
Dewey Steadman
United Therapeutics Corporation - Head of IR

Good afternoon, and welcome to the presentation of the INCREASE study results and pulmonary hypertension associated with interstitial lung disease. I'm Dewey Steadman, Head of Investor Relations at United Therapeutics.

Please note that our presentation today will include forward-looking statements, and I encourage you to read the risk factors in our most recent quarterly and annual reports filed with the SEC for risks and uncertainties that may cause our actual results to differ.

Today, we're pleased to have Dr. Steven Nathan, who's the Director of the Advanced Lung Disease Program and Director of the Lung Transplant Program at Inova Fairfax Hospital in Falls Church, Virginia and a key INCREASE study investigator. Dr. Nathan will dive into the INCREASE results.

Following Dr. Nathan's presentation, Michael Benkowitz, our President and Chief Operating Officer of United Therapeutics, will provide an update on our commercial plan in PH-ILD, assuming an April approval of the pending supplemental new drug application.

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot